Biomarker Expression in PBMCs for Hepatitis B Treatment Response

A prospective study of HBeAg-negative chronic hepatitis B patients treated with Peg-IFN-α and followed for 48 weeks. The dataset contains mRNA expression levels of ADAR1, N4BP1, and PSME1 in peripheral blood mononuclear cells, correlated with virological and serological response outcomes. The data was authored by Hao Pang and shared under a CC-BY-4.0 license on figshare.

Use Cases

• Predicting virological response to Peg-IFN-α treatment based on ADAR1, N4BP1, and PSME1 mRNA levels.
• Assessing the likelihood of HBsAg clearance based on biomarker expression dynamics.
• Evaluating the diagnostic performance of molecular biomarkers using ROC curve analysis.
• Conducting multivariate analysis to identify independent factors associated with therapeutic response.

Strengths

• Includes specific performance metrics (AUC values) for three biomarkers, such as ADAR1's AUC of 0.9230 for predicting VR.
• Reports clear clinical outcome rates, including a 47.25% virological response rate and a 35.16% serological response rate.
• Data is from a prospective study with a defined 48-week follow-up period.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (19.0 KB), indicating a limited scope.

Provenance

Source

figshare, author Hao Pang.

Collection Method

Real-time quantitative PCR detection of mRNA levels in PBMCs from a prospective clinical study.

Time Range

Study follow-up period of 48 weeks.

Freshness

Last updated 2026-04-13 04:36:07; freshness should be verified.

Geography

null